Haleon has expanded into dual-action pain relief with Panacombo Dual Action Pain Relief film-coated tablets.
The formulation (rsp: £3.50/10) combines 200mg of ibuprofen with 500mg paracetamol – which would help “shoppers break through pain when regular painkillers alone aren’t enough”, Haleon said.
“Panacombo Dual Action Tablets are stronger and faster than ibuprofen alone, designed to deliver effective pain relief from multiple pain types including migraine, headache, backache, dental pain, period pain, joint or muscular pain and aches linked with cold and flu.”
While ibuprofen acid alone provided effective pain relief in 37%-45% of cases, combining it with paracetamol increased effectiveness to 67%-70%, the supplier added. “Paracetamol helps to block pain signals and ibuprofen helps stop pain at the source.”
Available now in numerous retailers, Panacombo promises to work within five minutes and provide relief for up to nine hours.
“For 70 years, Panadol have been experts in pain relief, trusted to assist consumers with pain when needed,” said Michael Durkin, GB sales director at Haleon. “The launch of Panacombo, our dual-action pain-relief solution, expands our range of trusted products.”
The launch would provide retailers with “a strong proposition to help boost sales, encouraging shoppers to trade up and benefit from our trusted brand credentials”, he added.
Last week, Haleon announced a 2.2% increase in global revenue to £5.6m in the six months to 30 June 2026. Operating profit was down 2.6% to £1.2m, and organic revenue in Europe was flat, reflecting weak market conditions.
Overall, the supplier “delivered a good first half performance in what remains a challenging consumer environment, with sequential improvement in Q2 and a more balanced price and volume/mix”, said CEO Brian McNamara at the time.
“North America delivered further progress and emerging market growth accelerated particularly in China, India and Latin America. Oral health remained the standout performer supported by innovation and excellent in-market execution,” he added
“Looking ahead, while the external environment remains uncertain, we remain confident in our guidance for the year and our medium-term guidance, underpinned by strategic initiatives and the implementation of the new operating model, which will drive greater agility and further growth.”
No comments yet